Axa S.A. Halozyme Therapeutics, Inc. Transaction History

Axa S.A.

$33.6 Billion
Q2 2025

A detailed history of Axa S.A. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Axa S.A. holds 123,012 shares of HALO stock, worth $8.18 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

123,012

Previous 122,500 0.42%

Holding current value

$8.18 Million

Previous $7.82 Million 18.13%

% of portfolio

0.02%

Previous 0.03%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$47.91 - $70.14 $24,529 - $35,911	512 Added 0.42%	123,012 $6.4 Million
Q1 2025 May 15, 2025	SELL	$47.74 - $65.16 $448,326 - $611,917	-9,391 Reduced 7.12%	122,500 $7.82 Million
Q4 2024 Feb 14, 2025	BUY	$42.57 - $61.09 $1.01 Million - $1.46 Million	23,835 Added 22.06%	131,891 $6.31 Million
Q3 2024 Nov 14, 2024	BUY	$51.3 - $64.42 $5.54 Million - $6.96 Million	108,056 New	108,056 $6.18 Million
Q1 2024 May 15, 2024	BUY	$33.68 - $41.95 $2.86 Million - $3.56 Million	84,869 Added 168.61%	135,203 $5.5 Million
Q4 2023 Jul 16, 2024	SELL	$33.32 - $42.1 $2.83 Million - $3.57 Million	-84,869 Reduced 62.77%	50,334 $1.86 Million
Q4 2023 Feb 14, 2024	BUY	$33.32 - $42.1 $827,468 - $1.05 Million	24,834 Added 97.39%	50,334 $1.86 Million
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $65,628 - $79,254	1,800 Added 7.59%	25,500 $974,000
Q2 2023 Aug 14, 2023	SELL	$30.28 - $38.74 $427,705 - $547,202	-14,125 Reduced 37.34%	23,700 $854,000
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $70,747 - $119,922	2,153 Added 6.04%	37,825 $1.44 Million
Q4 2022 Feb 14, 2023	SELL	$40.06 - $59.44 $841,260 - $1.25 Million	-21,000 Reduced 37.06%	35,672 $2.03 Million
Q3 2022 Feb 14, 2023	BUY	$38.53 - $51.78 $1.98 Million - $2.67 Million	51,472 Added 989.85%	56,672 $2.24 Million
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $2.18 Million - $2.93 Million	56,672 New	56,672 $2.24 Million
Q2 2022 Aug 15, 2022	SELL	$37.35 - $48.3 $194,220 - $251,159	-5,200 Closed	0 $0
Q1 2022 Feb 14, 2023	SELL	$31.97 - $41.06 $1.65 Million - $2.11 Million	-51,472 Reduced 90.82%	5,200 $207,000
Q1 2022 May 13, 2022	SELL	$31.97 - $41.06 $2.77 Million - $3.55 Million	-86,500 Reduced 94.33%	5,200 $207,000
Q4 2021 Feb 14, 2022	SELL	$31.82 - $40.75 $1.08 Million - $1.39 Million	-34,000 Reduced 27.05%	91,700 $3.69 Million
Q3 2021 Nov 15, 2021	BUY	$38.47 - $46.42 $4.84 Million - $5.83 Million	125,700 New	125,700 $5.11 Million
Q1 2021 May 14, 2021	SELL	$39.51 - $51.45 $3.47 Million - $4.52 Million	-87,900 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$25.81 - $43.62 $2.27 Million - $3.83 Million	87,900 New	87,900 $3.75 Million
Q4 2019 Feb 18, 2020	SELL	$14.93 - $19.53 $373,250 - $488,250	-25,000 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$15.2 - $17.69 $6.25 Million - $7.28 Million	-411,419 Reduced 94.27%	25,000 $388,000
Q2 2019 Aug 13, 2019	BUY	$14.75 - $17.26 $120,979 - $141,566	8,202 Added 1.92%	436,419 $7.5 Million
Q3 2018 Nov 08, 2018	BUY	$16.68 - $18.41 $618,961 - $683,158	37,108 Added 9.49%	428,217 $7.78 Million
Q2 2018 Aug 13, 2018	BUY	$16.87 - $20.3 $6.6 Million - $7.94 Million	391,109 New	391,109 $6.6 Million

Others Institutions Holding HALO

# of Institutions

629

Shares Held

127M

Call Options Held

408K

Put Options Held

384K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $9.26B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.

Account